C5 and Alzheimer disease: A trial in AD patients with an inhibitor of late-stage complement activation such as Eculizumab (Soliris, Alexion Pharmaceuticals) [49], a humanized anti-C5 monoclonal antibody which prevents formation of C5b-9, might also help to resolve this issue.